CN Patent

CN119156372A — 使用米达美替尼的儿科患者的1型神经纤维瘤病(nf1)相关的丛状神经纤维瘤(pn)的治疗

Assigned to Springworths Treatment Co ltd · Expires 2024-12-17 · 1y expired

What this patent protects

本公开涉及用于治疗与1型神经纤维瘤病相关的丛状神经纤维瘤(NF1‑PN)的方法，其包括向有需要的儿科患者(例如，2至15岁)施用米达美替尼或其药学上可接受的盐。

USPTO Abstract

本公开涉及用于治疗与1型神经纤维瘤病相关的丛状神经纤维瘤(NF1‑PN)的方法，其包括向有需要的儿科患者(例如，2至15岁)施用米达美替尼或其药学上可接受的盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN119156372A
Jurisdiction
CN
Classification
—
Expires
2024-12-17
Drug substance claim
No
Drug product claim
No
Assignee
Springworths Treatment Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.